All In Biotech

Drug Trial Radar · NCT00589914

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Jun 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,221 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,221

Actual

Start

Mar 2007

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • RISPERDAL CONSTADrug

    RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.

  • Paliperidone palmitateDrug

    PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Positive and Negative Syndrome Scale (PANSS) Total Score for SchizophreniaTime frame: Baseline to the last postrandomization assessment in the double-blind treatment period (approximately 13 weeks)

Locations

82 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Cerritos, California

  • Site not named

    Garden Grove, California

  • Site not named

    Los Angeles, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Flowood, Mississippi

  • Site not named

    Hollis, New York

  • Site not named

    Willoughby, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    DeSoto, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Odessa, Texas

  • Site not named

    Linz, Austria

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Brno, Czechia

  • Site not named

    Dobřany, Czechia

  • Site not named

    Kroměříž, Czechia

  • Site not named

    Kutná Hora, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Pärnu, Estonia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Bourges Cedex N/A, France

  • Site not named

    Dole, France

  • Site not named

    Romans-sur-Isère, France

  • Site not named

    Achim, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Bielefeld, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Jena, Germany

  • Site not named

    Leipzig, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    München, Germany

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.